Novo Nordisk’s Wegovy pill is gaining significant traction in the GLP-1 market, challenging Eli Lilly’s anticipated dominance with its Foundayo pill. Wegovy’s strong launch, driven by effective marketing and perceived efficacy advantages, is forcing investors to reassess the competitive landscape. Both companies are contributing to the expansion of the GLP-1 market, attracting patients who previously avoided injections.
READ MORE FROM CNBC
Novo Nordisk's Wegovy Pill Gains Traction
The launch of Novo Nordisk's Wegovy pill in January has significantly boosted the GLP-1 drug market, with telehealth provider LifeMD reporting a doubling of new patients almost overnight – from 300-400 to 600-1,000 daily. This surge indicates increased access to these medications, according to both drugmakers and telehealth providers.
Eli Lilly's Foundayo Faces Early Challenges
While Eli Lilly introduced its Foundayo pill three months after Wegovy, its initial rollout appears less impactful. Analysts initially favored Lilly due to its claims of easier manufacturing and avoiding peptide shortages, but Novo's early success has shifted expectations.
Efficacy and Marketing Strategies
Novo Nordisk capitalized on a perceived advantage in efficacy, highlighting Wegovy's nearly 17% weight loss in trials compared to Foundayo's 12%. A robust promotional campaign, including ads in New York subways, TV broadcasts, and a Super Bowl ad featuring DJ Khaled, further propelled Wegovy's visibility. Novo emphasized the pill's $149 monthly price and efficacy comparable to the injection.
Expanding the GLP-1 Market
Both Wegovy and Foundayo are expanding the GLP-1 market by attracting patients previously hesitant due to needle aversion or cost concerns. Telehealth platform Sesame reports a significant preference for pills over shots, with a growing number of male patients entering the market.
Competition and Future Outlook
Eli Lilly is working to build brand awareness for Foundayo, with over 20,000 people starting the drug and 1,000 new patients daily. While Novo's Wegovy has a head start, analysts suggest it will take a year or two to fully assess the competition. Lilly's strong overall GLP-1 business and plans for international expansion offer potential for growth. Novo is investing $500 million in Ireland to meet demand for its oral products outside the U.S., with European approval expected later this year.
Investor Considerations
Investors are closely watching Novo's first-quarter earnings for insights into Wegovy's momentum. Despite potential sales declines due to generic competition in other markets and the pill's lower price point, Novo's pipeline remains a key focus. Analysts believe both companies have the potential to excel, with the pill market being a significant, but not defining, factor in their success.
